buy SingJoint Medical Sodium

buy SingJoint Medical Sodium Hyaluronate Gel

buy SingJoint Medical Sodium is used for intra-articular injection. It is an orthopedics agent for joint lubricant protection for joint cartilage and assisting therapy for osteoarthritis. It is for patients who do not get enough relief from simple painkillers such as acetaminophen or from exercise and physical therapy.

Singjoint Medical Sodium Hyaluronate is indicated for the treatment of symptomsof osteoarthritis of knee. By replacing and supplementing the pathological synovia fluid in the osteoarthritic joints, it reduces pain and improves joint function..

Medical Sodium Hyaluronate Gel, being animal-origin free and of high viscoelasticity, lubricity, physical alterability and good compatibility, it is polymer extracted and refined by high-tech bio-engineering from stretococcal fermentation metabolities. It is sterile, and free from pyrogenicity, allergy, genetic toxicity or skin irritation.

A systematic search was performed to select the appropriate results, all published by the end of April 2018. No limitations were imposed towards the past, as the concept of single injection is relatively new for SV in knee osteoarthritis. There were no restrictions on the country where each study was performed, but only articles published in English were considered.
A first selection was made after a quick review of titles and abstracts, then full texts were assessed to determine their eligibility. Special care was taken to eliminate duplicate publications at different levels of the search. Animal trials, laboratory tests, general articles, reviews, meta-analyzes, recommendations (guidelines), or author opinions were also eliminated.

In the end, articles were not included if they described buy SingJoint Medical Sodium :

• A context different from the current practice of SV in knee osteoarthritis: another joint, surgery or other associated pathology.
• A multi-injection protocol (more than one IA injection per treatment).
• A clinical trial carried out with a product not approved as a mono-injection of IA HA: European Union (EU) or USA.
• A planned combination of treatments, without the use of IA HA alone.
• or, insufficient data for WOMAC A.
Data processing
Data from the articles were taken into account as published and no questions were directed to any of the authors. A great effort was made to include all possible studies: when necessary and justified, SE and SD were estimated from the p-value, or the values ​​were measured on the available graphs. No alternative pain assessment was accepted to compensate or supplement missing data for WOMAC A.

The data were acquired and processed in MS Excel. Interpretation was made according to the description contained in each study. The data was recorded per arm studied for both the IA AH mono-injections and the placebo comparator injections.